在SCLC中探索YAP1相关的TIME:对免疫化疗的生存和治疗反应的影响
Yu-Qing Chen1,2,3,4, Jia-Xiong Tan1,2,3,4, Ling-Ling Gao5,4
1Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin 300060, China.
Cancer drug resistance (Alhambra, Calif.)
|March 7, 2025
概括
在小细胞肺癌 (SCLC) 中YAP1表达与预后不佳和抑制性瘤免疫微环境 (TIME) 相相关. 在接受基于阿特佐利祖马布的化疗的患者中,高YAP1表明无进展生存率较差.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症研究 癌症研究
背景情况:
- 小细胞肺癌 (SCLC) 呈现出晚期和不良预后.
- 由于免疫细胞透稀少,SCLC表现出有限的免疫疗法反应.
- 了解瘤免疫微环境 (TIME) 对SCLC治疗至关重要.
研究的目的:
- 调查YAP1和TIME在扩展阶段小细胞肺癌 (ES-SCLC) 的预后价值.
- 评估YAP1表达,TIME组件和患者生存结果之间的关系.
主要方法:
- 在15名ES-SCLC患者的活检样本上使用多种免疫组织化学 (mIHC),这些患者接受了阿特佐利祖马布/卡博普拉丁/埃托化物 (ECT) 治疗.
- 在瘤微环境中评估YAP1,CD56,CD4和FOXP3的表达.
- 与无进展生存率 (PFS) 和总生存率 (OS) 相关的标记表达,通过公开数据验证.
主要成果:
- 较高的YAP1阳性细胞群与PFS和潜在的OS相反相关.
- 鉴定出CD56阳性细胞是SCLC副体和层体中关键的TIME组件.
- YAP1的表达与CD4阳性细胞以及在体中与FOXP3阳性细胞正相关.
结论:
- 在接受ECT的SCLC患者中,YAP1显示出预后意义.
- 较高的YAP1水平似乎与免疫抑制性TIME有关.
- 建议进行进一步的大规模前性研究来证实这些发现.
更多相关视频
09:55All-optical Mechanobiology Interrogation of Yes-associated Protein in Human Cancer and Normal Cells using a Multi-functional System
Published on: December 20, 2021
2.9K
11:32Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
6.7K
相关概念视频
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
